Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.36 |
| ▸ | CASP7 | P55210 | 4/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.30 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.30 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10273862 | 1.00 | CASP3 (0.36) | CASP3CASP7NOS1PDK1PDK2 | |
| SCHEMBL21733403 | 1.00 | CASP3 (0.36) | CASP3CASP7NOS1PDK1PDK2 | |
| SCHEMBL21733378 | 1.00 | CASP3 (0.36) | CASP3CASP7NOS1PDK1PDK2 | |
| SCHEMBL24176145 | 1.00 | CASP3 (0.36) | CASP3CASP7NOS1PDK1PDK2 | |
| SCHEMBL18461688 | 0.85 | ALOX5 (0.33) | — | |
| SCHEMBL23158043 | 0.82 | NOS1 (0.30) | NOS1 | |
| SCHEMBL23158046 | 0.82 | NOS1 (0.30) | NOS1 | |
| SCHEMBL22062833 | 0.80 | — | — | |
| SCHEMBL24854605 | 0.80 | PDK1 (0.33) | PDK1 | |
| SCHEMBL22062975 | 0.79 | ALDH1A1 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023225252-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF RAS | THERAS, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| US-11760744-B2 | Fused ring compounds | GENENTECH, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| WO-2023133183-A1 | KRAS INHIBITORS | THERAS, INC. (US) | 2023-07-13 | — | — | WO | disclosed |
| WO-2023133181-A1 | KRAS INHIBITORS | THERAS, INC. (US) | 2023-07-13 | — | — | WO | disclosed |
| WO-2023086383-A1 | SELECT KRAS G12C INHIBITORS AND USES THEREOF | 1200 PHARMA LLC (US) | 2023-05-19 | — | — | WO | disclosed |
| WO-2023004102-A2 | COMPOSITIONS AND METHODS FOR INHIBITION OF RAS | THERAS, INC. (US) | 2023-01-26 | — | — | WO | disclosed |
| US-20230002345-A1 | FUSED RING COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-01-05 | — | — | US | disclosed |
| WO-2022262797-A1 | COMBINATION OF AN ERK INHIBITOR AND A KRAS INHIBITOR AND USES THEREOF | SHANGHAI ANTENGENE CORPORATION LIMITED (CN) | 2022-12-22 | — | — | WO | disclosed |
| US-20220081413-A1 | SYNTHESIS OF QUINAZOLINE COMPOUNDS | GENENTECH, INC. (US) | 2022-03-17 | — | — | US | disclosed |
| WO-2021216770-A1 | SUBSTITUTED TETRAHYDROQUINAZOLINE COMPOUNDS AS KRAS INHIBITORS | ACCUTAR BIOTECHNOLOGY INC. (US) | 2021-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220081413-A1 | SYNTHESIS OF QUINAZOLINE COMPOUNDS | COQ8A, SQSTM1, QARS1 | CASP3 3530/4885CASP7 3358/4885NOS1 2444/4885 |
| US-11760744-B2 | Fused ring compounds | KRAS, NRAS, HRAS | CASP3 3166/4885CASP7 2259/4885NOS1 3294/4885 |
| US-20230002345-A1 | FUSED RING COMPOUNDS | KRAS, NRAS, HRAS | CASP3 3166/4885CASP7 2259/4885NOS1 3294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.